A	B	C
1	Main
2		Brand Name	Remodulin
3		Administration	Oral
4		Competition	Gleevec, riociguat, macitentan
5		Clinical Trials
6			FREEDOM-C2 - Results in 2011.
7			Change in 6MW from baseline to week 16 is primary endpoint.
8
9
10			FREEDOM-M - Patients on background oral therapies - 16 week study n=350 Data in 2010 - delayed to 2011.
11			Monotherapy showed 25-30M improvement in 6MW
12			Citigroup expectation is <20M.
13
14
15			FREEDOM-C n=354
16			6MW at week 16 showed a 11 meter change, p=0.072.
17			6MW at week 12 showed a 13 meter change, p=0.015.
18
19
20			Phase 1 PK data - ATS 2008
21
22
23			p2a data in oral remodulin - pushed back due to manufacturing issues - one dose more variable than the others
24			October 2006 - begin the study - n=150 monotherapy and n=300 combination, interim analysis at 150 patients